Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Now Covered by Wedbush

Wedbush began coverage on shares of Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) in a report issued on Thursday morning, MarketBeat reports. The brokerage issued an outperform rating and a $22.00 target price on the stock.

Separately, William Blair reaffirmed an “outperform” rating on shares of Telix Pharmaceuticals Limited American Depositary Shares in a report on Wednesday, March 12th.

Telix Pharmaceuticals Limited American Depositary Shares Stock Down 3.4%

TLX stock opened at $16.77 on Thursday. The business has a fifty day moving average price of $16.76 and a 200 day moving average price of $16.85. Telix Pharmaceuticals Limited American Depositary Shares has a fifty-two week low of $13.61 and a fifty-two week high of $30.36.

Institutional Investors Weigh In On Telix Pharmaceuticals Limited American Depositary Shares

An institutional investor recently bought a new position in Telix Pharmaceuticals Limited American Depositary Shares stock. ABC Arbitrage SA purchased a new stake in shares of Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 26,939 shares of the company’s stock, valued at approximately $451,000.

Telix Pharmaceuticals Limited American Depositary Shares Company Profile

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.